SEP 15, 2015 08:00 AM PDT

WEBINAR: Custom Microarray as a Companion Assay for Exome Sequencing

Speakers
  • Director, R & D, Claritas Genomics
    Biography

      Yiping Shen is a ACMG-board certified medical director at Claritas. He has over 20 years’ experience in human genetic research and over 10 years’ experience in clinical molecular testing service. He also directed the R&D activity at the Genetic Diagnostic Laboratory (GDL) at Boston Children’s Hospital and developed and updated many tests including MLPA based targeted copy number tests, microarray based whole genome CNV+SNP test, as well as Sanger and Next Generation Sequencing based tests. He co-directs the R&D at Claritas. He has published numerous articles on the discovery of novel disease genes and contributed to a better understanding of genotype-phenotype correlations that are the basis for clinical interpretation and counseling. His research interests in understanding the genetic causes of pediatric genetic disorders, particularly developmental disorders, provide unique value for the genetic diagnostic testing service for pediatric patient population at Claritas.

      Dr. Shen is a reviewer for more than 10 academic journals and has been invited for many talks both nationally and internationally. He also provides training for research and clinical fellows and teaches for the Harvard Genetic Training program from which he was initially trained. He is an assistant professor at the Pathology Department at Harvard Medical School. He is also on the Faculty at Jiaotong University in Shanghai.

      Dr. Shen received the Master of Science in Developmental Biology at Wuhan University, China. He received his PhD in Pharmacology from Upstate Medical University, Syracuse, New York. He did his clinical genetics fellowship training in the Harvard Genetics Training Program. He is board-certified in Clinical Molecular Genetics. He is a Diplomate of the American Board of Medical Genetics.


    Abstract:
    Chromosomal microarray analysis (CMA) is an established technology, which has demonstrated great sensitivity and specificity for detecting genome-wide copy number variants (CNVs). CMA represents a robust technical platform for both medical genetics research and clinical services. Next generation sequencing technologies are now being widely used for genome or exome-wide detection of sequence variants. While whole genome and exome sequencing can produce information about large genomic imbalances, there is a sensitivity gap for detecting CNVs at the level at which they will be most useful, namely, at the level of a single exon. Custom microarrays designed to cover specific regions of interest on an exome, or even the whole exome, with high-density copy number probes are able to largely close this gap. We custom-designed and validated a microarray which looks in depth at over 600 clinically-relevant genes in pediatric neurology. We demonstrated that the array can detect copy number variants below a 1 kilobase level and that this level of resolution is necessary for maximal utility and impact.

    "For Research Use Only. Not for use in diagnostic procedures."

    Show Resources
    You May Also Like
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    JUL 30, 2019 10:00 AM PDT
    C.E. CREDITS
    JUL 30, 2019 10:00 AM PDT
    DATE: July 30, 2019TIME: 10:00am PT/ 1:00pm ET The importance of building a validation structure within your lab cannot be overstated. Once in place, the ability to identify high...
    Loading Comments...
    Show Resources